These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8828957)

  • 21. [The combined therapy of Basedow's ophthalmopathy with retrobulbar radiotherapy and i.v. immunoglobulins. The preliminary results].
    Antonelli A; Saracino A; Alberti B; Melosi A; Cartei F; Lepri A; Laddaga M; Baschieri L
    Clin Ter; 1992 Jan; 140(1):25-31. PubMed ID: 1526094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy.
    Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
    Jpn J Ophthalmol; 2002; 46(5):563-7. PubMed ID: 12457917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive treatment of Graves' ophthalmopathy.
    Wiersinga WM
    Thyroid; 1992; 2(3):229-33. PubMed ID: 1422236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy.
    Hiromatsu Y; Tanaka K; Sato M; Kuroki T; Nonaka K; Kojima K; Nishimura H; Nishida H; Kaise N
    Endocr J; 1993 Feb; 40(1):63-72. PubMed ID: 7951498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy.
    Kahaly G; Pitz S; Müller-Forell W; Hommel G
    Clin Exp Immunol; 1996 Nov; 106(2):197-202. PubMed ID: 8918563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy.
    Wang PW; Hiromatsu Y; Laryea E; Wosu L; How J; Wall JR
    J Clin Endocrinol Metab; 1986 Aug; 63(2):316-22. PubMed ID: 3755139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The lack of specificity of ophthalmic immunoglobulins in Graves' disease.
    Kadlubowski M; Irvine WJ; Rowland AC
    J Clin Endocrinol Metab; 1986 Oct; 63(4):990-5. PubMed ID: 3755729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
    Brauer VF; Scholz GH
    Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy.
    Nagayama Y; Izumi M; Kiriyama T; Yokoyama N; Morita S; Kakezono F; Ohtakara S; Morimoto I; Okamoto S; Nagataki S
    Acta Endocrinol (Copenh); 1987 Dec; 116(4):513-8. PubMed ID: 3321820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.
    Bednarek J; Wysocki H; Sowiński J
    Immunol Lett; 2004 May; 93(2-3):227-32. PubMed ID: 15158621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithyroglobulin monoclonal and autoantibodies cross-react with an orbital connective tissue membrane antigen: a possible mechanism for the association of ophthalmopathy with autoimmune thyroid disorders.
    Kuroki T; Ruf J; Whelan L; Miller A; Wall JR
    Clin Exp Immunol; 1985 Nov; 62(2):361-70. PubMed ID: 3841305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.
    Kendall-Taylor P; Crombie AL; Stephenson AM; Hardwick M; Hall K
    BMJ; 1988 Dec; 297(6663):1574-8. PubMed ID: 2906260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism.
    Kubota S; Gunji K; Ackrell BA; Cochran B; Stolarski C; Wengrowicz S; Kennerdell JS; Hiromatsu Y; Wall J
    J Clin Endocrinol Metab; 1998 Feb; 83(2):443-7. PubMed ID: 9467555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy.
    Tagami T; Tanaka K; Sugawa H; Nakamura H; Miyoshi Y; Mori T; Nakao K
    Endocr J; 1996 Dec; 43(6):689-99. PubMed ID: 9075609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Affinity purification of orbital membrane antigens for the study of the pathogenesis of Graves' ophthalmopathy.
    Salvi M; Bingoye F; Chung F; Wall JR
    J Clin Endocrinol Metab; 1988 May; 66(5):939-45. PubMed ID: 3360902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of antibodies in Graves' ophthalmopathy].
    Molnár I; Balázs C
    Orv Hetil; 1991 Sep; 132(38):2097-100. PubMed ID: 1923482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
    De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.